Agilent Technologies 'Well Positioned' to Accelerate Sales Growth in 2027, UBS Says

MT Newswires Live

Oct 09

Agilent Technologies (A) is "well positioned" to accelerate its sales growth to at least 6% in fiscal 2027 and beyond driven by various growth vectors, UBS said in a Tuesday report.

Recent launches of liquid chromatography and mass spectrometry instruments for pharmaceutical labs as well as increasing demand in China and the company's Nucleic Acid Solutions Division are expected to "provide idiosyncratic growth," the analysts said.

Agilent's exposure to China and oligonucleotide therapeutics is seen as underappreciated and could boost growth and valuation multiples, the report said.

The investment firm upgraded Agilent to buy from neutral and raised its price target to $170 from $130.

Shares of the company were up 2.7% in recent Wednesday trading.

Price: 142.27, Change: +3.71, Percent Change: +2.68

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2574979303"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574979303\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574979303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 02:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574979303","market":"hk","top_or_hot":-1,"title":"Agilent Technologies 'Well Positioned' to Accelerate Sales Growth in 2027, UBS Says","media":"MT Newswires Live","content":"<html><body><p> Agilent Technologies (A) is \"well positioned\" to accelerate its sales growth to at least 6% in fiscal 2027 and beyond driven by various growth vectors, UBS said in a Tuesday report.</p><p>Recent launches of liquid chromatography and mass spectrometry instruments for pharmaceutical labs as well as increasing demand in China and the company's Nucleic Acid Solutions Division are expected to \"provide idiosyncratic growth,\" the analysts said.</p><p>Agilent's exposure to China and oligonucleotide therapeutics is seen as underappreciated and could boost growth and valuation multiples, the report said.</p><p>The investment firm upgraded Agilent to buy from neutral and raised its price target to $170 from $130.</p><p>Shares of the company were up 2.7% in recent Wednesday trading.</p><p>Price: 142.27, Change: +3.71, Percent Change: +2.68</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies 'Well Positioned' to Accelerate Sales Growth in 2027, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies 'Well Positioned' to Accelerate Sales Growth in 2027, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-09 02:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Agilent Technologies (A) is \"well positioned\" to accelerate its sales growth to at least 6% in fiscal 2027 and beyond driven by various growth vectors, UBS said in a Tuesday report.</p><p>Recent launches of liquid chromatography and mass spectrometry instruments for pharmaceutical labs as well as increasing demand in China and the company's Nucleic Acid Solutions Division are expected to \"provide idiosyncratic growth,\" the analysts said.</p><p>Agilent's exposure to China and oligonucleotide therapeutics is seen as underappreciated and could boost growth and valuation multiples, the report said.</p><p>The investment firm upgraded Agilent to buy from neutral and raised its price target to $170 from $130.</p><p>Shares of the company were up 2.7% in recent Wednesday trading.</p><p>Price: 142.27, Change: +3.71, Percent Change: +2.68</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"A","symbol_name":"安捷伦科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2574979303","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574979303","pubTimestamp":1759948047,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Agilent Technologies  is \"well positioned\" to accelerate its sales growth to at least 6% in fiscal 2027 and beyond driven by various growth vectors, UBS said in a Tuesday report.Recent launches of liquid chromatography and mass spectrometry instruments for pharmaceutical labs as well as increasing demand in China and the company's Nucleic Acid Solutions Division are expected to \"provide idiosyncratic growth,\" the analysts said.Agilent's exposure to China and oligonucleotide therapeutics is seen as underappreciated and could boost growth and valuation multiples, the report said.The investment firm upgraded Agilent to buy from neutral and raised its price target to $170 from $130.Shares of the company were up 2.7% in recent Wednesday trading.Price: 142.27, Change: +3.71, Percent Change: +2.68","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"A":"安捷伦科技","AAQC":"Accelerate Acquisition Corp"},"translate_title":"瑞银表示，安捷伦科技“处于有利地位”，可以在2027年加速销售增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1.5,"AAQC":1.5},"content_text":"Agilent Technologies (A) is \"well positioned\" to accelerate its sales growth to at least 6% in fiscal 2027 and beyond driven by various growth vectors, UBS said in a Tuesday report.Recent launches of liquid chromatography and mass spectrometry instruments for pharmaceutical labs as well as increasing demand in China and the company's Nucleic Acid Solutions Division are expected to \"provide idiosyncratic growth,\" the analysts said.Agilent's exposure to China and oligonucleotide therapeutics is seen as underappreciated and could boost growth and valuation multiples, the report said.The investment firm upgraded Agilent to buy from neutral and raised its price target to $170 from $130.Shares of the company were up 2.7% in recent Wednesday trading.Price: 142.27, Change: +3.71, Percent Change: +2.68","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}